SAN FRANCISCO - Vir Biotechnology, Inc. (NASDAQ:VIR) announced Monday the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026, according to a press release statement.
Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he participated in the company’s transition from a clinical-stage biotechnology company to a commercial pharmaceutical company. Before Neurocrine, he held the position of vice president of financial services at Catholic Health Initiatives. He also worked as a senior manager in the health sciences practice of Ernst & Young LLP.
Coughlin currently chairs the board of directors of aTyr Pharma, Inc. and serves on the boards of ADC Therapeutics SA and Travere Therapeutics, Inc. He previously served on the boards of Fate Therapeutics, Inc. and Peloton Therapeutics, Inc. before its acquisition by Merck in 2019.His financial expertise comes as Vir navigates a critical growth phase. The company holds more cash than debt on its balance sheet and maintains a current ratio of 7.11, though it continues to burn through cash as it advances its clinical programs.
He holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Coughlin is a certified public accountant in California and Pennsylvania.
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for infectious diseases and cancer. The company’s clinical-stage portfolio includes programs for chronic hepatitis delta and T-cell engagers for solid tumor indications.The stock has delivered strong returns recently, up 57% over the past year and 30% in the last six months. According to InvestingPro analysis, the stock currently trades above its Fair Value. Investors can access comprehensive analysis through VIR’s Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Vir Biotechnology reported its first-quarter earnings for 2026, which revealed a significant shortfall in both earnings per share (EPS) and revenue expectations. The company posted an EPS of -$0.85, substantially missing the forecasted -$0.10, representing a 750% negative surprise. Additionally, revenue came in at -$29,000, falling short of the projected $55.89 million. These financial results have been a focal point for investors seeking insights into the company’s performance. In other developments, Vir Biotechnology announced that it will present data from its Phase 2 SOLSTICE trial at the EASL Congress 2026 in Barcelona. The trial evaluates the efficacy and safety of tobevibart alone or combined with elebsiran for chronic hepatitis delta virus infection. The presentation, which has been selected for inclusion in Best of EASL 2026, will be delivered by Tarik Asselah. These recent developments highlight the ongoing activities and challenges faced by Vir Biotechnology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.